Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies

Breast Cancer Research and Treatment

Volumn 38, Issue 1, 1996, Pages 11-17

  Beerli, Roger R ^a   Wels, Winfried ^b   Hynes, Nancy E ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Autocrine and intracrine growth inhibition; EGF receptor; ErbB 2; Fv domain; Monoclonal antibody

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; SIGNAL PEPTIDE;

ANIMAL CELL; CELL GROWTH; CELL SURFACE; CONFERENCE PAPER; ENDOPLASMIC RETICULUM; GROWTH INHIBITION; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CELL TRANSFORMATION, NEOPLASTIC; GENE THERAPY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS;

EID: 0030044484     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01803779     Document Type: Conference Paper

References (32)

1. Peles E, Yarden Y: Neu and its ligands: from an oncogene to neural factors. Bioessays 15:815-824, 1993
2. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47:87-98, 1991
3. Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Sem Cancer Biol 4:19-26, 1993
4. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172, 1989
5. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M: Mechanistic aspects of the opposing effects of monoclonal antibodies to ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 88:8691-8695, 1991
6. Harwerth I-M, Wels W, Schlegel J, Mueller M, Hynes NE: Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 68:1140-1145, 1993
7. c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54:3758-3765, 1994
8. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994
9. Buchdunger E, Trinks U, Mett H, Regenass U, Mueller M, Meyer T, McGlynn E, Pinna LA, Traxler P, Lydon NB: 4,5-dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci USA 91:2334-2338, 1994
10. Weis W, Harwerth I-M, Mueller M, Groner B, Hynes NE: Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52: 6310-6317, 1992
11. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR: Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 89:5867-5871, 1992
12. Pai LH, Gallo MG, Fitzgerald DJ, Pastan I: Antitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40). Cancer Res 51:2808-2812, 1991
13. Moritz D, Wels W, Mattern J, Groner B: Cytotoxic T lymphocytes with a grafted recognition specificity for ErbB-2 expressing tumor cells. Proc Natl Acad Sci USA 91:4318-4322, 1994
14. Beerli RR, Weis W, Hynes NE: Intracellular expression of single-chain antibodies reverts ErbB-2 transformation. J Biol Chem 269:23931-23936, 1994
15. Beerli RR, Wels W, Hynes NE: Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophys Res Commun, in press
16. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M: Single-chain antigen binding proteins. Science 242:423-426, 1988
17. Huston JS, Levinson D, Mudgett-Hunter M, Tai S-S, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879-5883, 1988
18. Orlandi R, Gucssow DH, Jones PT, Winter G: Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 86:3833-3837, 1989
19. erbB-2 specific single-chain antibody-toxins differ in their cell killing activity on tumor cells expressing both receptor proteins. Int J Cancer 60:137-144, 1995
20. Sunada H, Magun BE, Mendelsohn J, MacLeod CL: Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83:3825-3829, 1986
21. Fan Z, Masui H, Altas I, Mendelsohn J: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4328, 1993
22. Harwerth I-M, Wels W, Marte B, Hynes NE: Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 267:15160-15167, 1992
23. Wels W, Harwerth I-M, Zwickl M, Hardmann N, Groner B, Hynes NE: Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human ErbB-2 receptor. BioTechnology 10:1128-1132, 1992
24. Munro S, Pelham HRB: A C-terminal signal prevents secretion of luminal ER proteins. Cell 48:899-907, 1987
25. c-src kinase activity in FDC-P1 cells by polyoma middle-T antigen and hematopoietic growth factors. Oncogene 4:1433-1439, 1989
26. Pierce JH, Ruggiero M, Fleming TP, Di Fiore PP, Greenberger JS, Varticovski L, Schlessinger J, Rovera G, Aaronson SA: Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. Science 239:628-630, 1988
27. Morgenstern JP, Land H: Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucl Acids Res 18:3587-3596, 1990
28. neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969-3973, 1988
29. Goldman R, Ben-Levy R, Peles E, Yarden Y: Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29:11024-11028, 1990
30. erbB-2. J Biol Chem 268:2924-2923, 1993
31. Soltoff SP, Carraway KL, Prigent SA, Gullick WG, Cantley LC: ErbB-3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14: 3550-3558, 1994
32. Graus-Porta D, Beerli RR, Hynes NE: Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu Differentiation Factor and Epidermal Growth Factor signaling. Mol Cell Biol 15:1182-1191, 1995